Chronic lymphocytic leukemia.

@article{Chiorazzi2005ChronicLL,
  title={Chronic lymphocytic leukemia.},
  author={Nicholas Chiorazzi and Kanti R. Rai and Manlio Ferrarini},
  journal={The New England journal of medicine},
  year={2005},
  volume={352 8},
  pages={
          804-15
        }
}
From the Institute for Medical Research, North Shore–LIJ Health System (N.C., K.R.R.), and the Departments of Medicine, North Shore University Hospital, Manhasset, N.Y., and New York University School of Medicine, New York (N.C.); the Departments of Medicine, Long Island Jewish Medical Center, New Hyde Park, N.Y., and Albert Einstein School of Medicine, Bronx, N.Y. (K.R.R.); and the Division of Medical Oncology C, Istituto Nazionale per la Ricerca sul Cancro, and the Dipartimento di Oncologia… 

Figures and Tables from this paper

Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL).
TLDR
The ascertained incidence of CLL in the South Moravian Region is higher than declared incidence in the past, indicating that CLL became an often misdiagnosed and underreported disease.
From the Department of Oncology and Pathology Karolinska Institutet, Stockholm, Sweden Targeted monoclonal antibody therapy in chronic lymphocytic leukemia
TLDR
The results suggest that alemtuzumab may be effective in the treatment of severe AIHA in patients with progressive CLL who have failed to respond to conventional therapy.
Chronic lymphocytic leukemia.
Emerging Therapies in Chronic Lymphocytic Leukemia
TLDR
CLL treatments have seen the transition from single-agent alkyator-based therapies to nucleoside analogs, combination chemotherapy, and recently to monoclonal antibodies (MAbs) and chemoimmunotherapy, and the use of immunotherapy is emerging as an exciting modality with significant potential to advance the treatment of B-cell malignancies.
FCRL 2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia
TLDR
This study aims to demonstrate the efforts towards in-situ applicability of EMMARM, which aims to provide real-time information about the immune-oncology-drug-drug interactions between EMTs and cancer.
Results of chemotherapy in the treatment of chronic lymphoid leukemia in Black Africa: Experience of Cote d’Ivoire
  • NC Emeraude
  • Medicine
    Archives of Cancer Science and Therapy
  • 2019
TLDR
The objective of this study was to evaluate the place of polychemotherapy in the treatment of CLL of black African subjects and to identify their therapeutic and evolutionary characteristics.
Department of Medicine at Huddinge, Division of Hematology Karolinska Institutet, Stockholm, Sweden CLINICAL PROGNOSTIC MARKERS IN CHRONIC LYMPHOCYTIC LEUKEMIA
TLDR
The value of existing prognostic tools in order to develop new clinical prognostic markers for CLL is reviewed and the impact of clonal evolution and transformation in CLL in relation to biological markers and given therapy is assessed.
Prognostic Factors in Chronic Lymphoid Leukemia and Identification of New Clinically Relevant Molecular Markers
TLDR
The ultimate aim is to try and apply a targeted and early treatment that increases overall survival and quality of life in patients with more aggressive forms, and to determine reliably the cases who do not need further treatment.
A Retrospective Study of Leukemia in Libyan Children
TLDR
The results showed that ALL (73%) and AML (26%) are the most common types of leukemia occur in these children, and regardless gender type, the highest percentage was recorded between one month and 8 years of age.
Patterns of hematological and non-hematological malignancies in bone marrow in a tertiary care hospital in Nepal--11 years study.
TLDR
The authors' data reflects bone marrow malignancies in the Western region of Nepal which is more comparable to the Central than Eastern region of Nepalese, where males were more affected by multiple myeloma in their study.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 129 REFERENCES
A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis
TLDR
A new three‐stage classification in three prognostic groups only requires clinical examination and routine hemogram, has a good prognostic value which was confirmed on the series of Montserrat and Rozman (146 patients), and should therefore be helpful in planning new clinical trials.
Chronic lymphocytic leukemia: revelations from the B-cell receptor.
TLDR
Low responsiveness, expression of CD25, and production of immunosuppressive cytokines suggest that the cell of origin of CLL might be a regulatory B cell, and continuing regulatory activity, mediated via autoantigen, could suppress Ig production and lead to disease-associated hypogammaglobulinemia.
Chronic lymphocytic leukemia.
Chronic lymphocytic leukemia (CLL), the most frequent form of leukemia in Western countries, is characterized by the clonal proliferation and accumulation of neoplastic B lymphocytes in the blood,
The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL.
TLDR
A scoring system that gives for each of the most common marker profile in CLL a value of 1 or 0 according to whether it is typical or atypical for CLL will facilitate the diagnosis of B-lymphoproliferative disorders and improve their classification.
Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts.
TLDR
The monoclonal CLL phenotype cells present in otherwise healthy individuals may represent a very early stage of indolent CLL and should be useful in elucidating the mechanisms of leukemogenesis.
CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia.
TLDR
Multivariate analyses showed that CD38 expression is an important prognostic factor associated with high incidence of lymph node involvement and should become a routine test in the evaluation of patients with CLL.
Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b).
TLDR
The replacement of CD22 by SN8 in the original scoring system significantly increases its potential to discriminate between CLL and other B-cell lymphoproliferative diseases.
Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins.
TLDR
Looking at the immunoglobulin (Ig) heavy chain variable region genes used by leukemia cells of 1220 unrelated patients with chronic lymphocytic leukemia (CLL) provides compelling evidence that the Ig expressed by CLL B cells are highly selected and not representative of the Ig expression by naive B cells.
The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression.
TLDR
The presence of a distinct CD38(+) population within the leukemic clone, rather than a numerical cutoff definition, correlates with IgV(H) gene mutational status and, irrespective of its size, identifies CLL patients who will have progressive disease.
B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor.
TLDR
This review addresses the ability of antigens to select out and drive B cell clones from the normal state to overt leukemic cells by binding to BCRs that are relatively unique and characteristic of B-CLL cells.
...
1
2
3
4
5
...